<DOC>
	<DOCNO>NCT01472198</DOCNO>
	<brief_summary>This study compare efficacy simtuzumab ( GS-6624 ) versus placebo combination gemcitabine adult pancreatic cancer . The treatment phase study comprise 2 sequential part : open label treatment phase double-blinded treatment phase .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Simtuzumab Combined With Gemcitabine Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Initial diagnosis metastatic pancreatic cancer must occur â‰¤6 week prior completion screening . The presence measurable metastatic pancreatic cancer document contrast enhance CT ( MRI ) scan addition 1 following : 1 . Histological diagnosis pancreatic adenocarcinoma confirm pathologist OR 2 . Pathologist confirm histological/cytological diagnosis adenocarcinoma consistent pancreatic origin conjunction either : 1 . The presence mass pancreas OR 2 . A history resect pancreatic carcinoma Measurable disease per RECIST ( ver . 1.1 ) ECOG Performance Status 0 1 . Adequate hepatic , hematologic renal function . A history evidence clinically significant disorder metastatic cancer pancreas . A diagnosis pancreatic islet neoplasm . Subject undergone major surgery diagnosis surgery within 4 week randomization Presence biliary obstruction require external drainage Brain metastasis . Unstable cardiovascular function within last 6 month screen Clinically active liver disease , include active viral hepatitis ( HBV HCV ) cirrhosis Known HIV infection . Uncontrolled hypertension Screening History presence form cancer , pancreatic cancer , within 3 year prior enrollment Prior concurrent antitumor therapy ( chemotherapy , antibody therapy , molecular target therapy , retinoid therapy , hormonal therapy ) treatment inoperable locally advanced metastatic pancreatic cancer ; prior radiotherapy chemotherapy give preoperative neoadjuvant therapy radio sensitizer locally advance pancreatic cancer allow . Uncontrolled systemic fungal , bacterial viral infection Participation investigational drug device trial therapeutic intent within 30 day prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>GSI</keyword>
	<keyword>Gilead</keyword>
	<keyword>Gilead Sciences</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>PC</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Phase II</keyword>
	<keyword>GS-6624</keyword>
	<keyword>Oncology</keyword>
	<keyword>Monoclonal Antibody</keyword>
</DOC>